PMID: 10496924Sep 25, 1999Paper

Conservation and accessibility of an inner core lipopolysaccharide epitope of Neisseria meningitidis

Infection and Immunity
Joyce S PlestedE Richard Moxon


We investigated the conservation and antibody accessibility of inner core epitopes of Neisseria meningitidis lipopolysaccharide (LPS) because of their potential as vaccine candidates. An immunoglobulin G3 murine monoclonal antibody (MAb), designated MAb B5, was obtained by immunizing mice with a galE mutant of N. meningitidis H44/76 (B. 15.P1.7,16 immunotype L3). We have shown that MAb B5 can bind to the core LPS of wild-type encapsulated MC58 (B.15.P1.7,16 immunotype L3) organisms in vitro and ex vivo. An inner core structure recognized by MAb B5 is conserved and accessible in 26 of 34 (76%) of group B and 78 of 112 (70%) of groups A, C, W, X, Y, and Z strains. N. meningitidis strains which possess this epitope are immunotypes in which phosphoethanolamine (PEtn) is linked to the 3-position of the beta-chain heptose (HepII) of the inner core. In contrast, N. meningitidis strains lacking reactivity with MAb B5 have an alternative core structure in which PEtn is linked to an exocyclic position (i.e., position 6 or 7) of HepII (immunotypes L2, L4, and L6) or is absent (immunotype L5). We conclude that MAb B5 defines one or more of the major inner core glycoforms of N. meningitidis LPS. These findings support the possibility that i...Continue Reading


Mar 1, 1991·Microbial Pathogenesis·M VirjiE R Moxon
Apr 1, 1989·Clinical Microbiology Reviews·C E Frasch
Jan 1, 1987·Antonie van Leeuwenhoek·H J JenningsF Michon
Jun 1, 1982·Microbiological Reviews·I W DeVoe
Jun 1, 1995·Molecular Microbiology·J P van Putten, B D Robertson
Sep 1, 1993·Microbiological Reviews·C A Schnaitman, J D Klena
Jan 1, 1994·Methods in Enzymology·M A ApicellaH Schneider
Mar 1, 1993·Microbiological Reviews·A F VerheulJ T Poolman
Jan 1, 1996·Advances in Experimental Medicine and Biology·J T Poolman
Jan 1, 1996·Critical Reviews in Microbiology·A PrestonM A Apicella
Nov 1, 1996·The Journal of Infection·A A Al'Aldeen, K A Cartwright
Jun 11, 1997·Gene·X NassifM K Taha
Feb 18, 1998·JAMA : the Journal of the American Medical Association·N RosensteinB A Perkins
Apr 18, 1998·Proceedings of the National Academy of Sciences of the United States of America·M C MaidenB G Spratt
Apr 21, 1998·Nature·L SteeghsP van der Ley

❮ Previous
Next ❯


Apr 16, 2003·European Journal of Biochemistry·Andrew D CoxJames C Richards
Mar 30, 2004·The Journal of Biological Chemistry·Wei ZouHarold J Jennings
Jan 19, 2006·Clinical Microbiology Reviews·Lee H Harrison
Mar 11, 2008·Organic & Biomolecular Chemistry·Karin MannerstedtStefan Oscarson
Jul 26, 2012·Cellular Microbiology·Paola QuattroniRachel M Exley
Dec 1, 2001·Expert Opinion on Biological Therapy·A Riddell, J Buttery
Jan 9, 2004·Expert Review of Vaccines·Stefania Vergnano, Paul Heath
Dec 2, 2005·Expert Opinion on Biological Therapy·Kirsten P Perrett, Andrew J Pollard
Aug 30, 2002·European Journal of Biochemistry·Andrew D CoxJames C Richards
Aug 25, 2006·Clinical and Vaccine Immunology : CVI·Mohamed El KhattabiJord Stam
Jul 26, 2005·Infection and Immunity·Karen RobinsonDlawer A A Ala'Aldeen
Apr 3, 2003·Hospital Medicine·S Segal, A J Pollard
Jun 3, 2009·Expert Review of Vaccines·Susan LewisAndrew J Pollard
Feb 24, 2001·Journal of Bacteriology·D ArkingD C Stein
Feb 21, 2002·Infection and Immunity·Svein Rune AndersenSimon Y C Wong
Apr 29, 2019·Archivum Immunologiae Et Therapiae Experimentalis·Małgorzata MieszałaAndrzej Gamian
Nov 4, 2000·Nature Medicine·Y H SunC M Tang
Oct 29, 2005·Scandinavian Journal of Immunology·H TiwanaB M Charalambous
Jan 9, 2004·Expert Review of Vaccines·Clementien L Vermont, Germie P J M van den Dobbelsteen
Dec 12, 2001·Vaccine·S L Morley, A J Pollard
May 4, 2002·Lancet·Luis JódarDan M Granoff

❮ Previous
Next ❯

Related Concepts

Related Feeds